Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
100%(9 trials)

Phase Distribution

Ph phase_1
1
11%
Ph phase_3
8
89%

Phase Distribution

1

Early Stage

0

Mid Stage

8

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 3Large-scale testing
8(88.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(9)

Detailed Status

Completed9

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 38 (88.9%)

Trials by Status

completed9100%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_3

Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

NCT01890434
completedphase_3

SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

NCT00522951
completedphase_1

A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children

NCT00468819
completedphase_3

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients

NCT00395460
completedphase_3

Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging

NCT00709852
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT01890434Phase 3

Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

Completed
NCT00522951Phase 3

SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

Completed
NCT00468819Phase 1

A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children

Completed
NCT00395460Phase 3

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients

Completed
NCT00709852Phase 3

Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging

Completed
NCT01104584Phase 3

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)

Completed
NCT01067976Phase 3

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI

Completed
NCT00623467Phase 3

Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging

Completed
NCT00395733Phase 3

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9